Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Aerosol Medicine and Pulmonary Drug Delivery"
DOI: 10.1089/jamp.2019.1547
Abstract: Background: Wixela® Inhub® is a dry powder inhaler approved as a generic equivalent to Advair® Diskus® (fluticasone propionate [FP]/salmeterol fixed-dose combination) for patients with asthma or chronic obstructive pulmonary disease (COPD). This study aimed at… read more here.
Keywords: advair diskus; wixela inhub; day;
Wixela Inhub: Dosing Performance In Vitro and Inhaled Flow Rates in Healthy Subjects and Patients Compared with Advair Diskus
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Aerosol Medicine and Pulmonary Drug Delivery"
DOI: 10.1089/jamp.2019.1584
Abstract: Background: Wixela™ Inhub™ is a fluticasone propionate/salmeterol dry powder inhaler developed as a generic equivalent of Advair Diskus® for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Wixela Inhub and Advair Diskus are… read more here.
Keywords: advair diskus; wixela inhub; inhub; flow rates ... See more keywords
In Vitro Performance of the Wixela Inhub Inhaler Using Severe Chronic Obstructive Pulmonary Disease Patient Inhalation Profiles.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of aerosol medicine and pulmonary drug delivery"
DOI: 10.1089/jamp.2021.0017
Abstract: Background: Wixela Inhub (trademarks of Viatris, Inc.) is a dry powder inhaler (DPI) that delivers a fixed-dose combination of fluticasone propionate and salmeterol and is approved as a generic equivalent to Advair Diskus (trademarks of… read more here.
Keywords: inhaler; fluticasone propionate; wixela inhub; inhalation profiles ... See more keywords